HopeStage
Back to all studies
CompletedNCT05480046

Real-world risperidone outcomes after schizophrenia relapse

About this titleRead the official source — NCT05480046
Observational studyAges 18+Multiple countries
The study in practice

Understand this study

What did researchers investigate?

This study evaluated the effectiveness of Risperidone ISM for people with schizophrenia.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Listed locations
Aachen and 76 more locationsSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: October 18, 2022
Recruitment status
Completed
Enrollment listed in the registry
275
Sponsor
Rovi Pharmaceuticals Laboratories
Sponsor type
Pharmaceutical company
Study type
Observational
Intervention type
Drug
Locations
United Kingdom, Germany, Italy, ...
Age range
Over 18 Years
Official registry ID
NCT05480046
Official title
Show the full official title

Risperidone ISM® Effectiveness in Schizophrenia Patients Hospitalised Due to A Relapse: a Prospective Non-interventional Evaluation (RESHAPE Study)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Aachen, Germany · Ansbach, Germany · Bayreuth, Germany

65 more locations
  • Berlin, Germany
  • Bonn, Germany
  • Chemnitz, Germany
  • Dortmund, Germany
  • Eberswalde, Germany
  • Essen, Germany
  • Greifswald, Germany
  • Hamburg, Germany
  • Hemer, Germany
  • Leipzig, Germany
  • Mannheim, Germany
  • Munich, Germany
  • München, Germany
  • Neustadt, Germany
  • Werneck, Germany
  • Ancona, Italy
  • Bolzano, Italy
  • Brescia, Italy
  • Brindisi, Italy
  • Crema, Italy
  • Foggia, Italy
  • Legnano, Italy
  • Manfredonia, Italy
  • Milan, Italy
  • Montichiari, Italy
  • Palermo, Italy
  • Putignano, Italy
  • Sant'Agata di Militello, Italy
  • Vimercate, Italy
  • Beja, Portugal
  • Braga, Portugal
  • Coimbra, Portugal
  • Funchal, Portugal
  • Guarda, Portugal
  • Portimão, Portugal
  • Porto, Portugal
  • Santo Tirso, Portugal
  • Tomar, Portugal
  • Barcelona, Spain
  • Burgos, Spain
  • Córdoba, Spain
  • Granada, Spain
  • Huesca, Spain
  • Jaén, Spain
  • Jerez de la Frontera, Spain
  • L'Hospitalet de Llobregat, Spain
  • Las Palmas de Gran Canaria, Spain
  • Lleida, Spain
  • Lugo, Spain
  • Madrid, Spain
  • Majadahonda, Spain
  • Manacor, Spain
  • Manresa, Spain
  • Mataró, Spain
  • Móstoles, Spain
  • Murcia, Spain
  • Ourense, Spain
  • Ponferrada, Spain
  • Santander, Spain
  • Talavera de la Reina, Spain
  • Torrejón, Spain
  • Úbeda, Spain
  • Vigo, Spain
  • Vitoria-Gasteiz, Spain
  • London, United Kingdom

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

This study evaluated the effectiveness of Risperidone ISM for people with schizophrenia.

Who is behind this study?

The study sponsor is Rovi Pharmaceuticals Laboratories, a pharmaceutical company.

Did this study involve medication?

Yes. The study involved medication, including Risperidone ISM.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: from 18 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies